INsTRuCT Patients

MRC-based therapy holds great promise as a treatment for a wide range of immunologically-mediated diseases, including rheumatoid arthritis, multiple sclerosis and transplant rejection; however, this approach remains highly experimental and cannot be accessed except through clinical trials. The INsTRuCT Consortium is not itself sponsoring any studies, but several consortium partners are responsible for on-going and future clinical trials. Patients and physicians with an interest in these clinical studies are directed to the information and contacts listed below:

Multiple Sclerosis

H2020 ReSToRe is a joint initiative by researchers and clinicians from Belgium, Spain, the Netherlands and Germany to find a cure for Multiple Sclerosis (MS), a condition that affects the Brain and Spinal Cord.
Patients can connect to ReSToRe through Facebook

Rheumatoid Arthritis

Professor John Isaacs and Dr. Catharien Hilkens are pioneers of dendritic cell-based therapy in Rheumatoid Arthritis. More information about the AuToDeCRA project is available from the University of Newcastle ( and VersusArthritis ( websites.

Bone Marrow and Solid Organ Transplantation

ReSHAPE aims at transforming the treatment of patients suffering from undesired Immunity or Inflammation who presently have limited curative treatment options by applying next-generation Treg approaches that overcome the limitations of 1st generation Treg product developments.

Dendritic Cell (DC) vaccination against Cancer

DC vaccines stimulate immune responses against cancer and can overcome tolerance of immune effector cells induced by tumor cells. CiMaas is preparing for a Phase 1 clinical trial of DC-based vaccine in patients with non-small cell lung cancer. Patients will be treated using CiMaas’ proprietary DC platform in combination with the checkpoint inhibitor Nivolumab.